How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
DURHAM, N.C., March 29, 2016 -- In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.
Media contacts: Adam Daley Berry & Company Public Relations 212-253-8881 [email protected] Investor contact: John Menditto Argos Therapeutics, Inc. 919-908-0687 [email protected]
